Driven by the rising incidence of orthopedic disorders, increasing volume of spinal fusion procedures, and growing demand for advanced bone regeneration technologies, South Korea’s bone grafts and substitutes market is expected to witness steady expansion at a CAGR of 4% through 2033. This is further supported by the continued innovation in biologic bone graft materials and increasing adoption of synthetic bone substitutes, forecasts GlobalData, a leading intelligence and productivity platform.

GlobalData’s report, “Bone Grafts and Substitutes Market Size by Segments, Share, Regulatory, Reimbursement, Interventions and Forecast to 2036,” reveals that South Korea accounted for a sizable 8% share of the APAC bone grafts and substitutes market in 2025.

In this context, South Korea-based CGBIO has expanded its global NOVOSIS partnership with DePuy Synthes into North America and Australia through an exclusive commercialization and clinical development agreement. The partnership aims to support the broader adoption of NOVOSIS, a bone graft substitute portfolio that combines rhBMP-2(recombinant human Bone Morphogenetic Protein-2)-based bone regeneration technology with CGBIO’s sustained-release carrier platform technology to enhance bone regeneration and support complex spinal fusion and orthopedic procedures.

Prerna Gupta, Medical Devices Analyst at GlobalData, comments: “The expansion of the CGBIO–DePuy Synthes partnership underscores the growing industry focus on bone regeneration solutions in orthopedic care. As providers seek reliable bone healing outcomes and operational efficiency, such collaborations can improve product availability, clinical education, and market access potentially supporting wider adoption of bone graft substitutes in the markets they serve.”

Innovation in bone graft and substitute technologies spanning recombinant protein products, synthetic biomaterials, and regenerative platforms is broadening options for orthopedic and spinal procedures. As clinicians prioritize better outcomes, streamlined workflows, and minimally invasive techniques, advanced bone regeneration solutions are gaining traction.

Gupta concludes: “Building on these advances, wider clinical adoption will still vary by region due to differences in reimbursement, regulatory pathways, and local practice norms. However, continued innovation supported by strategic industry partnerships and an expanding base of clinical evidence is expected to drive broader commercialization and acceptance in the years ahead.”